Toll like receptor 2
Toll-like receptor 2 (TLR2) is a protein involved in innate immune signaling and is studied as a target in infection, inflammation, cancer, vaccine design, and small-molecule discovery.
Toll-like receptor 2 (TLR2) is a protein involved in innate immune signaling and is studied as a target in infection, inflammation, cancer, vaccine design, and small-molecule discovery. In the cited literature, TLR2 is connected to the TLR2/MyD88/NF-κB signaling pathway, which regulates inflammatory responses. Its signaling has been examined in relation to Interleukin-6 (IL-6), tumor-associated immune responses, the NLRP3 inflammasome, and other innate immune components.
TLR2 has also been described as the principal sensor associated with Mycoplasma pneumoniae infection, although the mechanisms that regulate the intensity of its signaling remain incompletely understood. These properties have made TLR2 a focus for antagonist development, receptor-directed antibodies, molecular docking and molecular dynamics studies, and investigations of its role in disease-associated immune remodeling.
Where the papers sit
9 papers from the last 6 months study toll like receptor 2 directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 2 human data · 7 preclinical
Themes one subject · 1 new direction
Those 9 are all about one subject.
-
TLR2 Modulation and Therapeutics
TLR2 research is converging on targeted control of innate immune signaling across infection, inflammation, pain, cancer and neurodegeneration. Antagonists, anti-TLR2 antibodies, engineered binders and CLEC5A/TLR2 bispecific antibodies aim to reduce pathogenic cytokine responses. Structure-based screening and molecular characterization are expanding the available small-molecule and biologic designs. Therapeutic evidence remains exploratory, with disease-specific mechanisms and clinical utility still to be established.
Mycoplasma pneumoniae infection reveals TLR2 as a scaffold for coordinated inhibitory-release and activating-receptor signaling
Mycoplasma pneumoniae infection was assumed to involve TLR2 primarily as the pathogen sensor that initiates inflammatory signaling, but the study instead found that TLR2 organizes a regulatory amplification network: TLR2-induced MMP-9 activates Neu1, which disrupts inhibitory Siglec-5–TLR2 interactions, while infection-induced Siglec-14 binds TLR2 and recruits Syk to sustain MAPK and NF-κB signaling. This changes TLR2 from a relatively direct inflammatory trigger into a platform whose output is controlled by coordinated receptor, sialidase, and kinase interactions, suggesting that interrupting this network may be more informative than targeting TLR2 activation alone. 42350323Jun
Papers
The 9 papers from the last 6 months that study toll like receptor 2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
TLR2 Modulation and Therapeutics (9)
- Identification of potential active ingredients from Chuanxiong Rhizoma in the treatment of vascular dementia: CHI3L1 and TLR2 are potential key targets. Medicine · 6 Nov 2026 PMID 42994846
- Modulating innate immune responses to curli fibers through protein engineering. Infection and immunity · 21 Sept 2026 PMID 42765877
- Structure-informed characterization of a TLR2-binding scFv reveals a CDR-centered recognition model. Biochemical and biophysical research communications · 15 Aug 2026 PMID 42603469
- Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex through TLR2-FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer. Scientific reports · 11 Aug 2026 PMID 42581056
- Development of recombinant anti-TLR2 antibodies and PLGA nanoparticle-based gene therapy for the treatment of neuropathic pain. Molecular therapy : the journal of the American Society of Gene Therapy · 30 Jul 2026 PMID 42528133
- Discovery and biological evaluation of novel TLR2 antagonists through structure-based virtual screening and molecular dynamics simulations. Bioorganic chemistry · 7 Jul 2026 PMID 42413396
- CLEC5A/TLR2 bispecific antibody suppresses dengue virus-induced pro-inflammatory cytokines production from macrophages. Journal of biomedical science · 29 Jun 2026 PMID 42374442
- Coordinated Regulation of TLR2 Signaling by Neu1 Sialidase and the Siglec-5/Siglec-14 Receptor Pair During Mycoplasma pneumoniae Infection. ACS infectious diseases · 25 Jun 2026 PMID 42350323
- Design, synthesis, and evaluation of 3-fluoro-2-hydroxybenzaldehyde derivatives as TLR2 small molecule antagonists. Bioorganic chemistry · 17 Jun 2026 PMID 42308788
By study type
Human data, design not indexed (2)
- Modulating innate immune responses to curli fibers through protein engineering. Infection and immunity · 21 Sept 2026 PMID 42765877
- CLEC5A/TLR2 bispecific antibody suppresses dengue virus-induced pro-inflammatory cytokines production from macrophages. Journal of biomedical science · 29 Jun 2026 PMID 42374442
Preclinical: animal, cell and lab studies (7)
- Identification of potential active ingredients from Chuanxiong Rhizoma in the treatment of vascular dementia: CHI3L1 and TLR2 are potential key targets. Medicine · 6 Nov 2026 PMID 42994846
- Structure-informed characterization of a TLR2-binding scFv reveals a CDR-centered recognition model. Biochemical and biophysical research communications · 15 Aug 2026 PMID 42603469
- Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex through TLR2-FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer. Scientific reports · 11 Aug 2026 PMID 42581056
- Development of recombinant anti-TLR2 antibodies and PLGA nanoparticle-based gene therapy for the treatment of neuropathic pain. Molecular therapy : the journal of the American Society of Gene Therapy · 30 Jul 2026 PMID 42528133
- Discovery and biological evaluation of novel TLR2 antagonists through structure-based virtual screening and molecular dynamics simulations. Bioorganic chemistry · 7 Jul 2026 PMID 42413396
- Coordinated Regulation of TLR2 Signaling by Neu1 Sialidase and the Siglec-5/Siglec-14 Receptor Pair During Mycoplasma pneumoniae Infection. ACS infectious diseases · 25 Jun 2026 PMID 42350323
- Design, synthesis, and evaluation of 3-fluoro-2-hydroxybenzaldehyde derivatives as TLR2 small molecule antagonists. Bioorganic chemistry · 17 Jun 2026 PMID 42308788
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-09-16. Drafted by language models from published abstracts; not medical advice.